Methylation silencing of TGF-β receptor type II is involved in malignant transformation of esophageal squamous cell carcinoma.
Yarui MaSiyuan HeAiai GaoYing ZhangQing ZhuPei WangBeibei YangHuihui YinYifei LiJinge SongPinli YueMo LiDandan ZhangYun LiuXiao-Bing WangMingzhou GuoYuchen JiaoPublished in: Clinical epigenetics (2020)
The characterization of methylation silencing of TGFBR2 in ESCC will enable us to further explore whether this epigenetic change could be considered as a predictor of malignant transformation in esophageal epithelial dysplasia and whether use of a TGFBR2 agonist may lead to a new therapeutic strategy in patients with ESCC.